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ORIGINAL ARTICLE
Introduction: Folate receptor alpha (FRα) and reduced folate car-
rier-1 (RFC1) regulate uptake of folate molecules inside the cell. 
FRα is a potential biomarker of tumors response to antifolate che-
motherapy, and a target for therapies using humanized monocloncal 
antibody. Information on the protein expression of these receptors in 
non–small-cell lung carcinoma (NSCLC) is limited.
Material and Methods: Expressions of FRα and RFC1 were exam-
ined by immunohistochemistry (IHC) in 320 surgically resected 
NSCLC (202 adenocarcinomas and 118 squamous cell carcinomas) 
tissue specimens and correlated with patients’ clinico-pathologic 
characteristics. Folate receptor  gene (FOLR1) mRNA expression 
was examined using publicly available microarray datasets. FRα 
expression was correlated with thymidylate synthase and p53 expres-
sion in NSCLCs, and with epidermal growth factor receptor (EGFR) 
and V-Ki-ras2 Kirsten rat sarcoma viral (KRAS) gene mutations in 
adenocarcinomas.
Results: NSCLC overexpressed FRα and RFC1. In a multivariate 
analysis, lung adenocarcinomas were more likely to express FRα in 
the cytoplasm (oR = 4.39; p < 0.0001) and membrane (oR = 5.34; 
p < 0.0001) of malignant cells than squamous cell carcinomas. Tumors 
from never-smokers were more likely to express cytoplasmic (oR = 
3.35; p<0.03) and membrane (oR = 3.60; p=0.0005) FRα than those 
from smokers. In adenocarcinoma, EGFR mutations correlated with 
higher expression of membrane FRα and FOLR1 gene expressions. 
High levels of FRα expression was detected in 42 NSCLC advanced 
metastatic tumor tissues.
Conclusions: FRα and RFC1 proteins are overexpressed in NSCLC 
tumor tissues. The high levels of FRα in lung adenocarcinomas may 
be associated to these tumors’ better responses to antifolate chemo-
therapy and represents a potential novel target for this tumor type.
Key Words: Non−small-cell lung carcinoma, Epidermal growth 
 factor receptor, membrane transporter, Folate receptor alpha, Reduced 
folate carrier-1.
(J Thorac Oncol. 2012;7: 833–840)
Lung cancer represents the first cause of death for cancer worldwide.1 Most patients with lung cancer are diagnosed at 
advanced metastatic stage (IV), requiring systemic treatment.1 
Two types of non–small-cell carcinoma (NSCLC), adenocarci-
noma and squamous cell carcinoma (SCC), are the most frequent 
(~80%) histological types of lung cancer.2 Despite intensive 
research on molecular targeted therapy, chemotherapy still rep-
resents the main treatment option for patients with advanced 
NSCLC.3 In addition, over recent years chemotherapy after sur-
gical resection has become the standard of care for treatment 
of selected patients with early-stage (i.e., stage IB, II, or IIIA) 
NSCLC.4 However, a subset of tumors does not respond to che-
motherapy, and most tumors develop drug resistance, leading to 
chemotherapy failure.2 The factors associated with chemotherapy 
resistance are not well understood, but some phenomena have 
been associated with this resistance, including, among others, 
decreases or alterations in the membrane transporters involved 
in drug-uptake systems or increase in drug-efflux pumps.5
Folate receptor alpha (FRα) and reduced folate carrier-1 
(RFC1) regulate cellular uptake of folate molecules inside the 
cell.5–7 Folates are required in the synthesis of nucleotide bases, 
amino acids, and other methylated compounds, and conse-
quently, they are required in larger quantities by proliferating 
cells.5 FRα is a glycoprotein that is anchored to the apical cell 
membrane of normal epithelial cells,8 and binds folate at a 
high affinity to mediate transport into the cytoplasm of cells.5 
RFC1 is more ubiquitously expressed in normal cells, binds 
folate at low affinity, and represents the sole folate-uptake 
pathway for most normal cells.7
FRα expression is upregulated in a range of human 
tumors, including ovarian, mesothelioma, lung, and colorec-
tal cancer.9–13 However, the level of expression of RFC1 in 
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tumors is less known. FRα has emerged as a potential marker 
for response to treatment of human carcinomas with the drug 
pemetrexed,14 a potent inhibitor of thymidylate synthase (TS) 
and other folate-dependent enzymes.15–17 Interestingly, FRα 
has been also investigated as a potential novel molecular target 
for human tumors.18–20 Recently, a humanized monoclonal anti-
body against FRα has been tested in a phase I clinical trial in 
patients with advanced chemorefractory ovarian carcinomas.19
In this study, we aimed to characterize the expression 
of FRα and RFC1 proteins in a large series (n = 320) of sur-
gically resected NSCLC tissue specimens with annotated 
clinico-pathologic features. In addition, we investigated the 
expression of FRα in a small series (n = 42) of advanced met-
astatic NSCLC tumor tissues. In surgically resected tumors we 
correlated the expression of FRα with the expression of TS. 
our findings of higher expression of FRα expression in lung 
tumors with adenocarcinoma histology and tumors obtained 
from never-smokers prompted us to correlate the expres-
sion of FRα with tumors’ epidermal growth factor receptor 
(EGFR) and KRAS mutation status in adenocarcinomas, and 
with tumors’ p53 protein expression in all NSCLCs.
METHODS
Case Selection and Tissue Microarray 
Construction
We obtained archived formalin-fixed and paraffin-
embedded (FFPE) NSCLC tissues from the Lung Cancer 
Tissue Bank at The University of Texas M. D. Anderson Cancer 
Center (Houston, TX). We selected lung cancer tissue speci-
mens from surgically resected NSCLCs with curative intent 
between 1997 and 2001, and constructed TMAs using three 
1-mm diameter cores. Detailed clinico-pathologic information 
was available for most cases (Table 1). In addition, we selected 
FFPE NSCLC tumor tissues from diagnostic tissue specimens 
from 42 advanced metastatic NSCLCs. The tissue specimens 
were histologically classified according to the 2004 World 
Health organization classification.2 The institutional review 
board at M. D. Anderson Cancer Center approved our study.
Immunohistochemical Staining and 
Evaluation
To test the expression of the membrane transporters, we 
used a monoclonal homemade antibody against FRα (clone 
Mb343, immunoglobulin G), dilution 1:500,13 and a poly-
clonal antibody against RFC1 (Abcam, Cambridge, MA), 
dilution 1:100. To assess the expression of TS, we used a 
monoclonal antibody (Zymed Carlsbad, CA), dilution 1:100. 
For p53 analysis, we used mouse monoclonal antihuman p53, 
clone Do7 (Dako, Carpinteria, CA), dilution 1:400.
For FRα we used a previously published IHC proto-
col.13 For RFC1 and TS, immunohistochemical staining 
was performed as follows: 5-µM FFPE tissue sections were 
deparaffinized and hydrated, and underwent heat-induced 
epitope retrieval in a DAKo antigen retrieval bath (Dako) 
at 121°C for 30 seconds and 90°C for 10 seconds in a 
decloaking chamber (Biocare, Concord, CA), followed by 
a 30-minute cool down. Before antibody immunostaining, 
endogenous peroxidase activity was blocked with 3% H
2
o
2
 
in methanol for 30 minutes. To block nonspecific antibody 
binding, tissue sections were incubated with 10% fetal bovine 
serum in Tris-buffered saline solution with Tween 20 for 30 
minutes. The slides were incubated with primary antibody at 
ambient temperature for 60 minutes for all antibodies. This 
was followed by incubation with biotin-labeled secondary 
antibody (Envision Dual Link +, DAKo) for 30 minutes. 
TABLE 1. Summary of Clinico-Pathologic Features of Patients with NSCLC Examined for Membrane 
Transporter and Thymidylate Synthase Expression
Feature
NSCLC Histologic Type
Squamous Cell Carcinoma
(n = 118)
Adenocarcinoma
(n = 202)
Total
(n = 320)
Mean age, years (SD), 
(range)
68.4 (9.20), (43–90) 64.9 (11.5), (33–88) 66.2 (10.85), (33–90)
Sex
 Male 73  77 150
 Female 45 125 170
Smoking statusa
 Never  4  52  56
 Ever 113 150 263
TNM stage
 I 62 134 196
 II 36  25  61
 III 18  36  54
 IV  2   7   9
aSmoking status and history were not available for one patient with squamous cell carcinoma.
NSCLC, non–small-cell lung carcinoma; TNM, Tumor, Node, Metastasis.
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Staining was developed with 0.05% 3’,3-diaminobenzidine 
tetrahydrochloride, which had been freshly prepared in 0.05 
mol/L Tris buffer at pH 7.6 containing 0.024% H
2
o
2
, and 
then the slides were counterstained with hematoxylin, dehy-
drated, and mounted.
Two observers (M.N. and I.W.) jointly quantified the 
immunohistochemical expression of the membrane transport-
ers (magnification ×20) in normal bronchial epithelium and 
lung tumor malignant epithelial cells. For each membrane 
transporter and TS, we defined three categories of intensity 
of immunostaining (0−3+). Next, an expression score (range, 
0–300) was obtained by multiplying the intensity of stain-
ing by the percent of cells (0%–100%) staining. p53 expres-
sion was categorized by percentage of tumor cells expressing 
nuclear p53 as positive (greater than or equal to 5%) or nega-
tive (0%–5%).
EGFR and KRAS Mutation Analysis
Exons 18 through 21 of EGFR and exon 1 of KRAS were 
amplified by polymerase chain reaction (PCR) using intron-
based primers as previously described.21,22
Assessment of Membrane Transporter 
Expression in Microarray Data Sets
The cancer microarray database and integrated data-
mining platform oncomine23 was utilized to analyze the 
expression of FOLR1 (FRα) and SLC19A1 (RFC1), and in 
microarray databases of NSCLC available online.24–27 The sta-
tistical significances of differences in expression of the genes 
were provided by oncomine and confirmed by a two-tailed 
t test with random variance. Gene expression data of lung 
adenocarcinomas with annotated mutation data of EGFR and 
KRAS were obtained from the Ladanyi and Gerald laboratories 
at the Memorial Sloan-Kettering Cancer Center (http://cbio.
mskcc.org/Public/lung_array_data/).28 Available Affymetrix 
raw data files of the transcriptomes of 190 adenocarcinomas 
(set I, n = 88; set II, n = 102) were analyzed using the BRB-
ArrayTools version 3.7.0 software developed by using the 
BRB-ArrayTools v.3.7.0 developed by Dr. Richard Simon 
and BRB-ArrayTools Development Team.29 Robust multiar-
ray analysis was used for normalization of gene expression 
data using the R language environment.30 FOLR1 mRNA 
expression levels in both Memorial Sloan-Kettering Cancer 
Center data sets were median-centered by the Cluster v.2.11 
software. Differences in normalized median-centered FOLR1 
expression levels were assessed for statistical significance by 
the two-tailed t test and p < 0.05 was considered statistically 
significant.
Statistical Methods
Associations between biomarker expression scores 
and patient clinico-pathologic data were assessed using the 
Wilcoxon ranked sum test or Kruskal-Wallis test, as appro-
priate, for continuous variables and the Chi-square test for 
categorical variables. The immunohistochemical expres-
sion of the markers was dichotomized in negative (score = 
0) and positive (score > 0) expressions based on the graphi-
cal distribution of the scores. For recurrence free survival 
(RFS) and overall survival (oS) analyses, we tested binary 
cutoff points of biomarkers using the median expression 
score for each marker. Univariate and multivariate Cox pro-
portional hazards regression models were used to assess the 
effects of covariates on survival. All statistical tests were 
two-sided, and p values <0.05 were considered statistically 
significant.
RESULTS
Expression of FR and RFC1 in Surgically 
Resected Tumors
Both adenocarcinoma and SCC expressed relatively 
high levels of FRα and RFC1 in the malignant cells (Fig. 1 
TABLE 2. Frequency of Membrane Transporters and Thymidylate Synthase Immmunohistochemical Expression in 
NSCLC by Tumor Histology
Marker
Any Expression (Score > 0) Average Score
Adenocarcinoma
Positive/Total (%)
SCC
Positive/Total (%) p Valuea
Adenocarcinoma
Score (SD)
SCC
Score (SD) p Valueb
FRα
 Cytoplasm 152/174 (87) 63/110 (57) <0.001 91.6 (66.4) 35.9 (40.3) <0.001
 Membrane 107/174 (61) 29/110 (26) <0.001 72.2 (89.0) 11.29 (28.8) <0.001
RFC1
 Cytoplasm 181/182 (99) 110/112 (98) 0.56 162.7 (83.2) 153.2 (72.0) 0.34
 Membrane 164/182 (90) 103/112 (92) 0.68 128.1 (95.9) 119.2 (86.1) 0.59
TS
 Cytoplasm 130/165 (79) 82/102 (80) 0.75 52.2 (40.1) 55.6 (42.0) 0.565
 Nuclear 58/165 (35) 59/102 (58) 0.0003 9.3 (21.1) 13.8 (27.7) 0.0043
aFisher’s exact test.
bWilcoxon ranked sum test.
SCC, squamous cell carcinoma; FRα, folate receptor alpha; RFC1, reduced folate carrier-1; TS, thymidylate synthase.
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and Table 2). For FRα, the average expression scores and fre-
quency of any expression (score > 0) were significantly higher 
in adenocarcinomas than in SCCs at membrane (p < 0.001) and 
cytoplasmic (p < 0.001) localizations (Fig. 2). Both NSCLC 
histologies demonstrated similar levels of cytoplasmic and 
membrane RFC1 expression. For both markers the tumor cells 
exhibited stronger immunohistochemical expression than the 
11 samples of normal bronchial epithelia adjacent to tumors 
(data not shown).
Correlation of FR and RFC1 Expression with 
Clinico-Pathologic Features in Surgically 
Resected Tumors
The multivariate analysis of the immunohistochemical 
expression of the two membrane transporters as a dichotomized 
variable (positive, score >0, vs. negative, score =0), after adjust-
ment for patient’s tumor histology, smoking history, sex, and 
disease stage, revealed that adenocarcinomas were more likely 
TS
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FIGURE 1. Photomicrographs showing immunohistochemical expression of folate receptor alpha (FR), reduced folate carrier-1 
(RFC1) and thymidylate synthase (TS) in non–small-cell lung carcinoma tissue specimens by histologic type. FR: (A), strong 
cytoplasmic and membrane expression in tumor cells; (B and C), moderate expression in tumor cells; (D), lack of expression in 
malignant cells. RFC1: (E and G), strong cytoplasmic expression in malignant cells. TS: (F and H), negative and moderate cyto-
plasmic and nuclear expression in tumor cells, respectively. Original magnification, ×200. FR, folate receptor alpha; TS, thymidy-
late synthase; RFC1, reduced folate carrier-1.
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FIGURE 2. FR expression scores by tumor histology. In the box-plots, indicates median scores. FR, folate receptor alpha.
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than SCCs to express cytoplasmic (odds ratio [oR] = 4.39; 
p < 0.0001) and membrane (oR = 5.34; p < 0.0001) FRα. In 
addition, tumors from never-smokers were significantly more 
likely to express cytoplasmic (oR = 3.35; p < 0.03) and mem-
brane (oR = 3.60; p = 0.0005) FRα than those of smokers. In 
the multivariate analysis, the patient’s sex was not an indepen-
dent significant factor influencing tumor expression of FRα. 
No correlation was found between expression of both mem-
brane transporters and RFS or oS in 230 patients with stage I 
or II NSCLCs (median follow-up, 7.2 years).
Correlation between FR Expression and 
Tumors’ p53 Expression and EGFR and KRAS 
Mutation Status
our findings of higher expression of FRα expression 
in lung tumors with adenocarcinoma histology and tumors 
obtained from never-smokers prompted us to correlate the 
expression of FRα with tumors’ EGFR and KRAS mutation 
status in adenocarcinomas, and with tumors’ p53 protein 
expression in all NSCLCs.
In lung adenocarcinomas, EGFR mutant tumors dem-
onstrated significantly higher expression scores for mem-
brane FRα (mean scores: mutant 134.8 versus wild-type 67.1; 
p = 0.002) than wild-type tumors (Fig. 3A). No correlation 
between FRα expression and adenocarcinoma tumors’ KRAS 
mutation status was detected.
of all NSCLCs tested, 38% (75 of 195) of adenocar-
cinomas and 69% (80 of 116) of SCCs had a positive p53 
level (5% or more). Interestingly, we found that the scores for 
FRα expression in both membrane (p = 0.001) and cytoplasm 
(p < 0.001) were significantly lower in malignant cells from 
NSCLC tumors with positive p53 expression (mean score: 
membrane 33.4, SD 59.9, and cytoplasm 58.3, SD 60.0) than 
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FIGURE 3. Folate Receptor alpha (FR) protein and mRNA expression scores in lung adenocarcinoma by  mutation status. FR 
protein expression was determined by immunohistochemistry (IHC), and mRNA expression is based in 2 publicly microarray 
data sets available.28 In the box-plots,  indicates median mRNA expression scores.
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in tumors with negative p53 expression (mean score: mem-
brane 65.3, SD 90.6, and cytoplasm 83.55.3, SD 65.3).
Expression of FR in Advanced  
Metastatic Tumors
To determine the levels of FRα expression in the entire 
spectrum of NSCLC, we examined FRα expression in 42 
tumor tissues obtained from advanced NSCLCs (27 from 
lung/pleural tumors and 15 from metastatic sites). The tumor 
histologies corresponded to 23 adenocarcinomas, 5 SCCs, and 
14 tumors classified as NSCLCs without features of specific 
histology (NSCLC—not otherwise specified). We found that 
advanced tumors demonstrated similar levels of FRα expres-
sion than surgically resected tumors by examining the average 
expression scores and frequency of any expression (score >0). 
Although small numbers, in the advanced tumors the FRα 
average expression scores were higher in adenocarcinomas 
than SCCs at membrane (mean score: adenocarcinoma 62.2. 
SD 81.2; SCC 20.0, SD 44.7; p = 0.042) and cytoplasmic 
(mean score: adenocarcinoma 104.1, SD 88.5; SCC 22.0, SD 
39.0; p = 0.319) locations. NSCLC—not otherwise specified 
showed intermediate levels of FRα expression (mean score: 
membrane 20.7, SD 56.9, and cytoplasm 64.6, SD 96.5). In 
advanced tumors, any membrane expression (score > 0) of 
FRα was detected in 48% (11of 23) of adenocarcinomas and 
20% (1 of 5) of SCCs, whereas cytoplasmic expression was 
observed in 78% (18 of 23) and 40% (2of 5) SCCs. No signifi-
cant difference in the expression of FRα was detected when 
comparing lung/pleural tumors with metastatic sites (data not 
shown).
FOLR1 mRNA Expression in Tumor Tissues
our findings that protein levels of FRα was greater in 
adenocarcinomas than in SCCs incited us to analyze expres-
sion levels of the mRNA of the FOLR1 in published micro-
array data sets of surgically resected (satges I–III) NSCLC 
tumor specimens and compare them by histologic type.24–27 
In accordance with our IHC data, FOLR1 mRNA expression 
levels were significantly higher in adenocarcinomas (n = 197) 
than in SCCs (n = 210) in all four data sets available: 1.8 ver-
sus 1.0 (p < 0.0001),25 0.81 versus 0.73 (p = 0.03),27 2.61 ver-
sus 0.98 (p < 0.0001),26 and 0.93 versus 0.31 (p < 0.0001).24
To confirm our findings on the increased FRα immuno-
reactivity in tumors obtained from EGFR mutant lung adeno-
carcinomas compared with wild type tumors, we probed this 
association using the mRNA expression levels of FOLR1 in 
publicly available microarray data sets with information on 
EGFR and KRAS mutation status.28 Notably, the analysis of 
the microarray data further revealed the statistically signifi-
cant upregulation of FOLR1 mRNA levels in EGFR mutant 
lung adenocarcinomas compared with wild-type tumors in both 
available data sets (p = 0.00016 and p = 0.003) (Fig. 3B and C). 
In addition, no statistically significant differences were found 
in FOLR1 expression levels between KRAS mutant lung ade-
nocarcinomas and wild-type tumors (data not shown). These 
findings confirm the close positive association between FOLR1 
expression and EGFR mutation status, which we had found at 
the protein level by assessment of FRα immunoreactivity.
Correlation of Immunohistochemical 
Expression of TS and FRα
TS was expressed frequently in the nucleus and cytoplasm 
of malignant NSCLC cells. However, the frequency of any TS 
expression (score > 0) was higher in the cytoplasm (212 of 267, 
79%) than in the nucleus (117 of 267, 44%). Although cyto-
plasmic expression of TS was similar in both NSCLC histologic 
types (Table 2), nuclear expression was significantly higher 
(p = 0.003) in SCCs (mean score: 13.8, SD 27.7) than in adeno-
carcinomas (mean score: 9.3, SD 27.1). The level of TS expres-
sion did not correlate with clinico-pathologic characteristics, 
including RFS and oS. In all NSCLC, significantly (p = 0.02) 
higher expression of nuclear TS immunostaining was detected 
in tumors with positive p53 expression (67 of 114, 58%) than in 
those with negative p53 staining (65 of 147, 44%). In adenocar-
cinomas, there was no correlation between TS expression and 
EGFR or KRAS mutation status.
We correlated the expression of TS and FRα in NSCLC 
tissue specimens. The score for nuclear TS expression corre-
lated negatively with the score for cytoplasmic FRα expression 
in SCCs (r = −0.20; p = 0.04), and showed marginally signifi-
cant negative correlation with membrane FRα expression in 
adenocarcinomas (r = −0.16; p = 0.05). When we examined 
the correlation of any expression (score > 0) of both markers 
in tumors, we found that in SCCs expression of nuclear TS 
was significantly inversely correlated (p = 0.03) with mem-
brane expression of FRα, and that most tumors positive for TS 
(62 of 79, 79%) lacked membrane FRα. This correlation was 
not detected in adenocarcinomas.
DISCUSSION
Membrane transporters FRα and RFC1 are considered 
potential biomarkers of tumor response to antifolate chemo-
therapy.14 In addition, FRα represents a novel target for ther-
apy in human carcinomas utilizing monoclonal antibodies.19,20 
Information on the protein expression of these receptors in 
NSCLC is limited. Here, we report for the first time that 
NSCLC frequently overexpresses both FRα and RFC1 pro-
teins by studying a large series of cases with annotated clini-
co-pathologic information. Importantly, we report that tumor 
cells from lung adenocarcinoma histology expressed signifi-
cantly higher levels of cytoplasmic and membrane FRα than 
SCC, and tumors from never-smokers were significantly more 
likely to express cytoplasmic FRα than those from smokers. 
In lung adenocarcinomas, the presence of EGFR mutations 
correlated with higher expression of membrane FRα and 
FOLR1 gene expression. NSCLC tissue specimens from 
advanced metastatic tumors showed similar levels of FRα 
expression than surgically resected tumors. We postulate that 
this information may be useful in selecting which patients with 
NSCLC may benefit from receiving treatment with antifolate 
inhibiting agents and monoclonal antibodies against FRα.
our study showed that RFC1 is expressed frequently in the 
membrane and cytoplasm of malignant cells of NSCLC tumor tis-
sues. Although RFC1 performs its important biological functions 
at the cell membrane, the cytoplasmic expression can be explained 
as part of synthesis of the protein.31 The only report available on 
the expression of RFC1 in human tumors showed relatively high 
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levels of mRNA gene expression in NSCLC, with similar expres-
sion in adenocarcinomas and SCCs.11 These data are consistent 
with our protein expression data showing that levels of expression 
of RFC1 were similar in the two histologic types.
Interestingly, in our study the expression of membrane 
and cytoplasmic FRα was significantly higher in surgically 
resected lung adenocarcinomas compared with SCCs. FRα is 
bound to the cell membrane which binds to folate and inter-
nalizes it in the cytoplasm through endocytosis.6 Similar trend 
was detected in a small set of advanced metastatic NSCLC 
tumor tissues. FRα has been shown by immunohistochemical 
studies to be overexpressed previously in small sets of NSCLC 
tissue specimens.11,12 However, to the best of our knowledge, 
there is no published report of FRα protein expression in 
NSCLC tumors and correlation with clinical and pathological 
features. our protein expression findings agree with the sig-
nificantly higher levels of expression of FOLR1 (FRα gene) 
mRNA in adenocarcinomas than in SCCs in all four public 
microarray data sets available.24–27 Similar findings have been 
reported in a quantitative PCR study of mRNA expression of 
119 NSCLC tissue specimens.11
The findings of higher levels of FRα protein and FOLR1 
mRNA expression in adenocarcinomas than in SCCs of the 
lung may have important clinical implications. The higher 
level of FRα protein expression in adenocarcinoma cells may 
explain the better response of advanced NSCLC of nonsqua-
mous histology when treated with the combination of cisplatin 
and the multitargeted antifolate agent pemetrexed.32 However, 
this needs to be further tested in NSCLC tumor tissue speci-
mens obtained from patients treated with pemetrexed. In 
addition, FRα is currently considered an attractive target for 
biologic therapy in tumors in which it is overexpressed com-
pared with corresponding normal epithelium such as ovarian 
cancer by using the humanized monoclonal antibody against 
FRα Farletuzumab.19,20 our findings of high expression of 
FRα in NSCLC compared with normal bronchial epithelium 
suggest that this protein could be considered a novel potential 
target for NSCLC, particularly in lung adenocarcinomas.
our finding that NSCLCs of never-smokers have a 
higher expression of FRα than those of smokers is of interest. 
our data showing significantly higher cytoplasmic and mem-
brane FRα expression in NSCLCs obtained from never-smok-
ers are in agreement with the previous report of higher levels 
of mRNA FOLR1 by quantitative PCR in adenocarcinomas 
from nonsmokers and light smokers than in those from heavy 
smokers.11 These differences in the expression of FRα by 
smoking status are consistent with our findings of higher FRα 
expression in NSCLCs lacking p53 expression and in adeno-
carcinomas harboring EGFR mutation, two features associated 
with the pathogenesis of non−smoking-related lung cancer.33 
of interest, the analysis of the publicly available microarray 
data confirmed at mRNA gene expression level our observa-
tion that EGFR mutant adenocarcinoma tumors expressed 
higher levels of FRα protein. There are not data available on 
the response to antifolate chemotherapy agents in lung adeno-
carcinomas based on EGFR mutation status. However, it has 
been shown that advanced stage adenocarcinoma harbour-
ing this mutation showed improved response to other type of 
(carboplatin and paclitaxel) chemotherapy.34
Because of their roles in metabolism of the chemother-
apy agent pemetrexed,14,35 we correlated the expressions of TS 
and FRα in NSCLC tissue specimens by histologic type. As 
previously reported,36,37 TS protein was expressed frequently in 
the nucleus (44%) and cytoplasm (79%) of malignant NSCLC 
cells. In our analysis, we determined that nuclear expression 
was significantly higher in SCCs than in adenocarcinomas. 
Ceppi et al.36 previously reported that immunohistochemical 
expression of TS mRNA and protein was significantly higher in 
SCCs of the lung than in adenocarcinomas. In this previously 
reported immunohistochemical analysis, however, expression 
of TS in the malignant cells was not distinguished as nuclear 
or cytoplasmic. It has been shown that low levels of TS mRNA 
expression significantly correlated with in vitro chemosensi-
tivity of freshly explanted human tumor specimens to pem-
etrexed.38 It has been hypothesized that the higher mRNA and 
protein expressions of TS observed in SCCs explains the lower 
rate of response to pemetrexed in this NSCLC type.32 Recently, 
Sun et al.39 reported that low immunohistochemical TS protein 
expression in tumors correlated with worse progression-free 
survival in stage IIIB and IV patients with nonsquamous cell 
lung carcinomas treated with pemetrexed.
When we correlated FRα and TS protein expression 
in NSCLC tumors, we found that in SCCs the expression of 
nuclear TS had a significant inverse correlation with expres-
sion of membrane FRα, and most TS-positive SCCs (79%) 
lacked membrane FRα immunostaining. Furthermore, we 
speculate that the more frequent occurrence of the FRα-
membrane–negative/TS-nuclear–positive expression pattern 
in lung SCCs than in adenocarcinomas could be associated 
with the lower response rate to pemetrexed in this tumor 
type. Although FRα is most biologically active at the cell 
membrane,6 there is strong evidence of the important role of 
TS as translational regulation in the nucleus of cells.40
In summary, our findings indicate that membrane trans-
porter FRα and RFC1 proteins are frequently overexpressed 
in NSCLC tissues. The higher level of FRα in adenocarcino-
mas than in SCCs may help explain differences in efficacy of 
antifolate chemotherapy between these tumor types. We pos-
tulate that this information may be useful in selecting which 
patients with NSCLC may benefit from and should receive 
treatment with antifolate inhibiting agents and with monoclo-
nal antibodies against FRα.
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